Protalix BioTherapeutics
PLX
66 hedge funds and large institutions have $17.9M invested in Protalix BioTherapeutics in 2023 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 7 closing their positions.
457% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 7
237% more call options, than puts
Call options by funds: $2.82M | Put options by funds: $838K
196% more capital invested
Capital invested by funds: $6.04M → $17.9M (+$11.9M)
150% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 6
94% more funds holding
Funds holding: 34 → 66 (+32)
8.17% more ownership
Funds ownership: 5.12% → 13.29% (+8.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.02M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.74M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.32M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$981K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$865K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$1.31M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$504K |
| 3 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$494K |
| 4 |
Two Sigma Investments
New York
|
-$331K |
| 5 |
Millennium Management
New York
|
-$156K |
PLX Hedge Fund Activity: Q2 2023 in Review
66 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q2 2023, worth a combined $17.9M — up 196% from $6.04M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new PLX positions and 7 closed out — a net gain of 32 holders — while 15 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $6.02M. The largest seller was Renaissance Technologies, cutting an estimated $1.31M.
- 66 institutional investors held Protalix BioTherapeutics (PLX) as of Q2 2023, up from 34 in Q1 2023.
- Funds reported $17.9M of Protalix BioTherapeutics stock for Q2 2023, up 196% quarter-over-quarter.
- 39 funds opened new Protalix BioTherapeutics positions in Q2 2023 and 7 closed out, a net change of +32 holders.
- The largest Protalix BioTherapeutics buyer in Q2 2023 was BlackRock, an estimated $6.02M added.
- The largest Protalix BioTherapeutics seller in Q2 2023 was Renaissance Technologies, an estimated $1.31M sold.
Based on aggregated 13F filings for Q2 2023.